Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01530 3SBIO
RTNominal down5.640 -0.060 (-1.053%)
Others

13/09/2018 14:39

[I-bank focus]Sino Biopharm (01177) seen hurt by new policy

[ET Net News Agency, 13 September 2018] China's National Medical Insurance Bureau
announced plans to test "volume-based drug procurement" in 11 big cities for 33 drugs with
generics that have passed the generic consistency appraisal (GCA).
UBS Global Research thinks generic players will be motivated to cut prices to
retain/gain volume share. As very few drugs are involved at this time, the research house
thinks the near-term impact on the overall industry is unclear, but the downward trend of
generic prices is inevitable as a way to save costs to enhance insurance coverage for
innovative drugs.
In the long term, UBS thinks the policy will have a profound impact on the market share
landscape, and originators' brand generics with high prices and generics with a high
volume share could be negatively affected.
Meanwhile, the shift to procurement-price-based insurance payments will likely also
facilitate the replacement of high-priced drugs. However, it thinks the impact on industry
profit could be milder than the price decline due to savings on drug marketing expenses
(which typically equals 30-40% of a drug's revenue).
UBS thinks Huahai (Shanghai code: 600521) could benefit, as four of its generics are the
only ones to have passed GCA so far. Salubris (Shenzhen code: 002294) could benefit in the
near term, as its generic is the only one that has passed GCA for Clopidogrel. Sino
Biopharmaceutical (01177) could be negatively impacted, as its biggest drug, entecavir
(~20% of revenue), has a ~60% volume share but is priced higher than other generics.
3SBio Inc. (01530) could be more defensive, as biomedicines are not impacted by GCA. The
policy could also help CSPC Pharmaceutical's (01093) albumin paclitaxel enter the market.
(KL)

Remark: Real time quote last updated: 23/09/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.